Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02636647 · ClinicalTrials.gov registry record · Phase 1
Fecal Transplant in Recurrent Hepatic Encephalopathy
A Phase 1 study, sponsored by Jasmohan Bajaj.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02636647: Completed Phase 1 study, sponsored by Jasmohan Bajaj.
NCT02636647 is a Phase 1 study that has completed, run by Jasmohan Bajaj. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02636647, a Phase 1 study, has completed, sponsored by Jasmohan Bajaj.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Randomized, open-label safety, tolerability study with exploratory endpoints and pathophysiological evaluation of the FMT Two groups of outpatients with cirrhosis will be randomized using random sequence generator into no-treatment and FMT groups.
Interventions
- BIOLOGICAL Fecal transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02636647
The ClinicalTrials.gov registry entry for NCT02636647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jasmohan Bajaj, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fecal transplant is the first listed.
NCT02636647 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02636647 about?
NCT02636647 is a clinical study titled "Fecal Transplant in Recurrent Hepatic Encephalopathy". Randomized, open-label safety, tolerability study with exploratory endpoints and pathophysiological evaluation of the FMT Two groups of outpatients with cirrhosis will be randomized using random sequence generator into no-treatment and FMT groups.
What is the current status of trial NCT02636647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-10. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02636647?
The interventions under investigation include: Fecal transplant (BIOLOGICAL).
Who is sponsoring clinical trial NCT02636647?
This trial is sponsored by Jasmohan Bajaj, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.